Escherichia coli are gram-negative bacteria that cause urinary tract infections (UTIs). UTIs have affected a significant percentage of humans yearly due to bacterial infection. Our study aims to determine the prevalence of resistance genes in E. coli towards sulfamethoxazole. This study included (490) patients with UTIs, and the urine samples were cultured on media. The patients were admitted to the Medical City in Baghdad to treat UTIs. 116 E.coli isolates were isolated from urine specimens, 35 isolates of them were resistant to trimethoprim/sulfamethoxazole, and 81 isolates were sensitive to trimethoprim/sulfamethoxazole; the E. coli isolates were submitted to multiplex PCR to detection some resistance genes (Sul1, sul2) after detected the isolates by PCR depending on 16S rRNA. Our study showed that identified E. coli was (91-99%) depending on the number of the examined samples by the Vitek 2 system. The molecular study included extraction of chromosomal DNA from (53) E. coli isolates; 35 samples were taken resistant to antibiotics, while from the total of 81 sensitive isolates, only 18 sensitive samples were taken from that are the most sensitive to Timethprime/sulfamethoxazole, then identification by 16S rRNA gene. Detection of Sulfonamides resistance genes included sul1 and sul2. The results showed the 16S rRNA gene identification found in all E. coli isolates and the detection of antibiotic resistance genes. The resistant isolates with the Sul1 gene prevalence were 11(31%), while the sensitive isolates with Sul1gene were 1(6%). Moreover, the resisted isolates with Sul2 gene prevalence was 8(23%), while the sensitive isolates with the Sul1 gene were 0(0%). The numbers of the resistant isolates were (11) and (8) that carry the Sul1 gene and Sul2 gene, respectively, while the numbers of the sensitive isolates were (1) and (0), respectively. We can conclude that a high percentage of Sul1 gene and Sul2 genes in E. coil isolated from UTIs were high. Keywords. UTI, Sul1, Sul2, resistant gene, trimethoprim-sulfamethoxazole
The capacity of Multiـdrug resistant (MDR) Acinetobacter baumannii to survive in any state of affairs concerning the gaining of various gene types of virulence and antimicrobial agent resistance are the main anxiety in the hospital’s environments. So, it is very crucial to determine the prevalence of insertion sequences in A. baumannii. In the hospitals. Detecting the blaoxa-51 gene through the polymerase chain reaction (PCR) was performed to confirm Acinetobacter baumannii and the search for ISAba1 element. Between October 2020 and February 2021, 540 distinct clinical specimens were gathered from five hospitals in Baghdad. Thirty-eight A. baumannii isolates were obtained from various clinical specimens. The isolates were initially identified phenotypically using standard microbiological techniques and by the Vitek2 compact automated machine. Isolates of A. baumannii were identified genotypically by amplification of the blaoxa-51-like gene. Antimicrobials are studied by Kirby-Bauer (disc diffusion) technique on Muller-Hinton agar as specified by the recent clinical and laboratory standard institute (CLSI) guidelines (2020). The actual results of the current study indicated that from total isolated (38) A.baumannii isolates, 23 isolates (61%) were resistant to meropenem and 25 isolates (66%) were resistant to imipenem. The blaoxa-51 gene was identified in all strains examined, ISAba1 was also present in all A. baumannii isolates. ISAba1 has a high predominance between drug-resistant A. baumannii. Identifying these parameters can assist in the control of infection and decreasing the microorganism’s prevalence rate.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.